Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
XSAT:DBP B's EV-to-EBITDA is ranked worse than 82.75% of 400
companies
in the Biotechnology industry
Industry Median: 13.615
vs XSAT:DBP B: 58.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Double Bond Pharmaceutical International AB (XSAT:DBP B) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Double Bond Pharmaceutical International AB's PE Ratio (TTM) for today is calculated as:
Double Bond Pharmaceutical International AB's share price for today is kr0.1165.
Double Bond Pharmaceutical International AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Double Bond Pharmaceutical International AB EV-to-EBITDA Chart
Double Bond Pharmaceutical International AB Annual Data
XSAT:DBP B vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Double Bond Pharmaceutical International AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Double Bond Pharmaceutical International AB EV-to-EBITDA vs Biotechnology Industry
Double Bond Pharmaceutical International AB's current Enterprise Value is kr25.59 Mil.
Double Bond Pharmaceutical International AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Double Bond Pharmaceutical International AB (XSAT:DBP B) has a EV-to-EBITDA of 58.28 as of Sep. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Double Bond Pharmaceutical International AB. According to the industry distribution chart, Double Bond Pharmaceutical International AB ranks #331 out of 400 companies in the Biotechnology industry, placing it in the top 82.7%.
Is Double Bond Pharmaceutical International AB's EV-to-EBITDA too high?
Double Bond Pharmaceutical International AB's current EV-to-EBITDA is 58.28. The Biotechnology industry median EV-to-EBITDA is 13.62. Double Bond Pharmaceutical International AB's value of 58.28 is 328.1% above this industry median. Based on the distribution chart, Double Bond Pharmaceutical International AB ranks #331 out of 400 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Double Bond Pharmaceutical International AB has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Double Bond Pharmaceutical International AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Double Bond Pharmaceutical International AB ranks #331 out of 400 companies for EV-to-EBITDA. This places Double Bond Pharmaceutical International AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.62. Double Bond Pharmaceutical International AB's value of 58.28 is 328.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.62, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Double Bond Pharmaceutical International AB's current EV-to-EBITDA of 58.28 is 328.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Double Bond Pharmaceutical International AB. For the Biotechnology industry, the median EV-to-EBITDA is 13.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Double Bond Pharmaceutical International AB's current EV-to-EBITDA is 58.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Double Bond Pharmaceutical International AB stock overvalued right now?
Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB (XSAT:DBP B) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.06, compared to a current price of kr0.12 — trading 94.2% above its estimated fair value. The current EV-to-EBITDA is 58.28 and 328.1% above the Biotechnology industry median of 13.62. Double Bond Pharmaceutical International AB's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Double Bond Pharmaceutical International AB (XSAT:DBP B), the current EV-to-EBITDA is 58.28 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Double Bond Pharmaceutical International AB (XSAT:DBP B) Overvalued in 2026?
Based on GuruFocus' analysis, Double Bond Pharmaceutical International AB stock appears to be overvalued.
The current stock price of kr0.12 is trading 94.2% above its estimated GF Value™ of kr0.06.
GuruFocus considers Double Bond Pharmaceutical International AB to be Significantly Overvalued.
Key valuation signals for XSAT:DBP B:
EV-to-EBITDA: 58.28
GF Value™: kr0.06 vs. price of kr0.12 (94.2% above fair value)
Industry Position: 328.1% above the Biotechnology median (#331 of 400)
No single metric tells the full story. See the XSAT:DBP B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Double Bond Pharmaceutical International AB is a pharmaceutical company. The company develops and commercializes approaches for the treatment of cancers, infections, autoimmune diseases, and other life-threatening disorders.
28GF Score
Get the complete analysis for XSAT:DBP B
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:DBP B has been successfully added to your 
